Home > Drugs A – Z > Triamcinolone (On the skin)

Triamcinolone (On the skin)

Treats skin itching, swelling, and other discomfort. This medicine is a corticosteroid.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Triamcinolone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid). This medicine is available only with your doctor's prescription… Read more
Brand names include
Aristocort A, Aristocort C Concentrate, Aristocort D Dilute, Aristocort R Ointment Regular, Aristocort R Regular, Cinolar, DermaSilkRx SDS Pak, DermacinRx SilaPak, DermacinRx Silazone PharmaPak, Dermasorb TA Complete Kit, Dermazone, Ellzia Pak, Kenalog, Kenalog Cream, Kenalog Ointment, Kenalog Spray, NuTriaRx, Pediaderm TA, Tri-Sila, Triacet, Triaderm Mild Cream, Triaderm Mild Ointment, Triaderm Regular Cream, Triaderm Regular Ointment, Triamcot, Trianex, Trianide Mild-Cream, Triderm, Whytederm TDPak, Whytederm Trilasil Pak, Zytopic
Other forms
By injection, For the teeth or gums, Injection route, Into the nose, Intra-articular route
Drug classes About this
Corticosteroid, Intermediate
Combinations including this drug

What works? Research summarized

Evidence reviews

Effectiveness and safety of laser photocoagulation plus intravitreal triamcinolone for diabetic macular edema: a meta-analysis

Bibliographic details: Xu CQ, Ma LJ.  Effectiveness and safety of laser photocoagulation plus intravitreal triamcinolone for diabetic macular edema: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012; 12(7): 817-821 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=2012070014

Clinical course and management of iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir: a systematic review

Bibliographic details: John G, Ollo D, Meyer P, Herold M, Samer CF, Calmy A.  Clinical course and management of iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir: a systematic review. Journal of Antivirals and Antiretrovirals 2013; 5(7): 180-184 Available from: http://omicsonline.org/clinical-course-and-management-of-iatrogenic-cushing-syndrome-jaa.1000086.php?aid=22049

Topical corticosteroids for treating phimosis in boys

Phimosis is a condition where the foreskin cannot be fully drawn back (retracted) over the penis. Phimosis is normal at birth and often self‐corrects without needing treatment during the first three to four years of life; only 10% of three year old boys have phimosis. This is known as congenital phimosis. Phimosis can also be caused by scarring of the skin protecting the head of the penis that is caused when the foreskin cannot be retracted. Phimosis caused by scarring is estimated to occur among 0.6% to 1.5% of boys less than 18 years of age, but this type of phimosis seldom occurs among boys under five years of age. Making a distinction between types of phimosis can sometimes be difficult.

See all (134)

Summaries for consumers

Topical corticosteroids for treating phimosis in boys

Phimosis is a condition where the foreskin cannot be fully drawn back (retracted) over the penis. Phimosis is normal at birth and often self‐corrects without needing treatment during the first three to four years of life; only 10% of three year old boys have phimosis. This is known as congenital phimosis. Phimosis can also be caused by scarring of the skin protecting the head of the penis that is caused when the foreskin cannot be retracted. Phimosis caused by scarring is estimated to occur among 0.6% to 1.5% of boys less than 18 years of age, but this type of phimosis seldom occurs among boys under five years of age. Making a distinction between types of phimosis can sometimes be difficult.

Steroids with antiangiogenic properties for treating neovascular age‐related macular degeneration

Neovascular age‐related macular degeneration (AMD) is associated with rapid loss of vision due to abnormal growth of blood vessels in the macula. Corticosteroids that reduce this growth of blood vessels have been tested for treatment of such vision loss. This review included three trials evaluating two different types of steroids, triamcinolone acetonide and anecortave acetate, for the treatment of neovascular AMD. The findings across the three trials, which included a total of 809 participants, were consistent with no evidence of benefit, in terms of preventing vision loss, with antiangiogenic steroids compared with placebo or photodynamic therapy. Based on available evidence, there is little benefit of steroids with anti‐angiogenic properties in the treatment of neovascular age‐related macular degeneration.".

Systemic corticosteroids for acute gout

‐ there is no precise information about side effects and complications. Only a minority of the patients treated with the steroid oral prednisolone reported minor side effects.

See all (24)

PubMed Health Blog...

read all...